BioSpace News Archive

Genetown

Incendia Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 38th Annual Meeting

Incendia Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 38th Annual Meeting.

October 31, 2023
·
2 min read
Deals

Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering

Avenue Therapeutics, Inc. today announced the pricing of its public offering of an aggregate of 16,633,400 units at a public offering price of $0.3006 per unit.

October 31, 2023
·
5 min read
Genetown

Affini-T Therapeutics to Present Preclinical Gene Editing Data from its Program Targeting KRAS G12D at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Affini-T Therapeutics to Present Preclinical Gene Editing Data from its Program Targeting KRAS G12D at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.

October 31, 2023
·
2 min read
Genetown

Nimbus Therapeutics Presents Positive Preliminary Data from Clinical Trial of HPK1 Inhibitor in Solid Tumors at SITC Annual Meeting

Nimbus Therapeutics today announced initial data from the company’s ongoing Phase 1/2 study of NDI-101150, a small-molecule inhibitor of HPK1, which are being presented in a poster at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA.

October 31, 2023
·
3 min read
Exactech Announces First Surgeries Using Activit-E™ for Knee Replacement

Exactech announced the successful first surgery using its new, advanced Activit-E™ polyethylene for the Truliant® knee replacement system.

October 31, 2023
·
3 min read
MustGrow Receives USDA Organic Approval for Biological Fertilizer and Soil Amendment Technology

MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company” or “MustGrow”) is pleased to announce receipt of organic compliance certification from the USDA National Organic Program

October 31, 2023
·
10 min read
Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, is reporting the outcome of a protocol-defined interim analysis

October 31, 2023
·
9 min read
Business

Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC

Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present new findings at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting regarding its first-of-its-kind collaboration with Moderna.

October 31, 2023
·
6 min read
Business

Fresenius Medical Care appoints Craig Cordola as new Management Board member for Care Delivery

Fresenius Medical Care has appointed Craig Cordola (52) as new Management Board member for the globally operating Care Delivery segment.

October 31, 2023
·
4 min read
Drug Development

Be Biopharma Presents Preclinical Data Demonstrating Ex-Vivo Engineered B Cell Medicines Produce Highly Active and Sustained Levels of Antitumor Biologics

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), will present preclinical data demonstrating that a BCM-derived biologic can deliver steady-state plasma concentrations of a bispecific T cell engager at clinically relevant doses for treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).

October 31, 2023
·
5 min read